Valsts: Austrālija
Valoda: angļu
Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)
dutasteride, Quantity: 500 microgram
Arrotex Pharmaceuticals Pty Ltd
Dutasteride
Capsule, soft
Excipient Ingredients: butylated hydroxytoluene; iron oxide yellow; Gelatin; titanium dioxide; glyceryl caprylate/caprate; glycerol; propylene glycol; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; simethicone; ethanol; Shellac; sulfuric acid
Oral
30
(S4) Prescription Only Medicine
This medicine is indicated for use as monotherapy for the management of symptomatic benign prostatic,hyperplasia (BPH) or as combination therapy with an alpha blocker which is approved for use in BPH and,which has been dose titrated in accordance with the relevant recommendations in the product information,for that alpha blocker.
Visual Identification: An oily colourless to pale yellow liquid absent of visible particles and/or crystals in a pale yellow oblong gelatin capsule printed with with 'A 0.5' on one side in red ink; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2014-02-28